Press Release
Printer Friendly Version View printer-friendly version
 « Back
Pernix Therapeutics to Report First Quarter 2017 Financial Results on Monday, May 15
Download PDF Download PDF

MORRISTOWN, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) a specialty pharmaceutical company, announced today that the Company will report financial results for the first quarter ended March 31, 2017, after the market close on Monday, May 15, 2017.  John Sedor, Chairman and Chief Executive Officer, and Graham Miao, President and Chief Financial Officer, will host a conference call to discuss the results.

Date:     Monday, May 15
Time:     4:30 PM ET
Toll free (U.S.):     888-504-7953
International:     719-457-2643
Conference ID:     4336660

About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market.  The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments.  The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core, cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.

To learn more about Pernix Therapeutics, visit

Investor Relations
Matthew P. Duffy, 212-915-0685
LifeSci Advisors, LLC

Primary Logo

Pernix Therapeutics Holdings, Inc.